

CITATION REPORT

List of articles citing

Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance

DOI: 10.1016/j.molcel.2014.05.015
Molecular Cell, 2014, 54, 716-27.

Source: <https://exaly.com/paper-pdf/59728391/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
710	Multiple system atrophy: genetic or epigenetic?. 2014 , 23, 277-91		20
709	Circulating Tumor Cells: Who is the Killer?. 2014 , 7, 161-76		26
708	Colorectal cancer stem cells: from the crypt to the clinic. 2014 , 15, 692-705		265
707	NOD-Like Receptors: Master Regulators of Inflammation and Cancer. 2014 , 5, 327		135
706	Epigenetics of hematopoietic stem cell aging and disease. 2014 , 100, 326-34		29
705	Experimental teratoma: at the crossroad of fetal- and onco-development. 2014 , 29, 75-9		9
704	Poised epigenetic states and acquired drug resistance in cancer. 2014 , 14, 747-53		195
703	Epigenetics of cancer stem cells: Pathways and therapeutics. 2014 , 1840, 3494-3502		96
702	Differential reactivation of fetal/neonatal genes in mouse liver tumors induced in cirrhotic and non-cirrhotic conditions. 2015 , 106, 972-81		32
701	IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. 2015 , 126, 1741-52		133
700	Abrupt loss of MLH1 and PMS2 expression in endometrial carcinoma: molecular and morphologic analysis of 6 cases. 2015 , 39, 993-9		27
699	Epigenetic regulation of chondrocyte differentiation. 2015 , 51, 105-113		5
698	Epigenetic treatment of solid tumours: a review of clinical trials. 2015 , 7, 127		136
697	Targeting tumor suppressor genes for cancer therapy. 2015 , 37, 1277-86		41
696	Intratumor heterogeneity and transcriptional profiling in glioblastoma: translational opportunities. 2015 , 10, 369-381		
695	Potential of epigenetic therapies in the management of solid tumors. 2015 , 7, 241-51		42
694	Graphene oxide selectively targets cancer stem cells, across multiple tumor types: implications for non-toxic cancer treatment, via "differentiation-based nano-therapy". 2015 , 6, 3553-62		150

693	Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy. 2015 , 4, 183-91	12
692	Cancer Stem Cells: Dynamic Entities in an Ever-Evolving Paradigm. 2015 , 7,	3
691	Targeting Cancer Stem Cells: Promises and Challenges. 2016 , 16, 38-58	28
690	Impact of Maternal Diet on the Epigenome during In Utero Life and the Developmental Programming of Diseases in Childhood and Adulthood. 2015 , 7, 9492-507	135
689	Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas. 2015 , 6, 32317-38	26
688	Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells. 2015 , 6, 14777-95	175
687	Characterisation of mesothelioma-initiating cells and their susceptibility to anti-cancer agents. 2015 , 10, e0119549	19
686	Environmental Epigenetics: Crossroad between Public Health, Lifestyle, and Cancer Prevention. 2015 , 2015, 587983	40
685	High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant. 2015 , 6, 30472-86	131
684	EpCAM-Antibody-Labeled Noncytotoxic Polymer Vesicles for Cancer Stem Cells-Targeted Delivery of Anticancer Drug and siRNA. 2015 , 16, 1695-705	43
683	Endoplasmic reticulum stress, genome damage, and cancer. 2015 , 5, 11	69
682	Developmental Insights into Breast Cancer Intratumoral Heterogeneity. 2015 , 1, 242-251	16
681	Evaluation of Epigenetic Drug Targeting of Heterogenous Tumor Cell Fractions Using Potential Biomarkers of Response in Ovarian Cancer. 2015 , 21, 5151-63	12
680	The other face of TLR3: A driving force of breast cancer stem cells. 2015 , 2, e981443	8
679	Genome-Wide Epigenetic Studies in Human Disease: A Primer on -Omic Technologies. 2016 , 183, 96-109	18
678	3-Deazaneplanocin A suppresses aggressive phenotype-related gene expression in an oral squamous cell carcinoma cell line. 2015 , 468, 269-73	6
677	Effects of deranged metabolism on epigenetic changes in cancer. 2015 , 38, 321-37	8
676	Translational horizons in the tumor microenvironment: harnessing breakthroughs and targeting cures. 2015 , 35, 408-36	45

675	DNA methylation-based subtype prediction for pediatric acute lymphoblastic leukemia. 2015 , 7, 11	40
674	Targeting Epigenetically Deregulated miRNA by Nutraceuticals: Focusing on Cancer Prevention and Treatment. 2015 , 1, 1-10	6
673	Epigenetic biomarkers in the blood of patients with urological malignancies. 2015 , 15, 505-16	45
672	Emerging role of PR domain containing 5 (PRDM5) as a broad tumor suppressor in human cancers. 2015 , 36, 1-3	18
671	Redox-active and redox-silent compounds: synergistic therapeutics in cancer. 2015 , 22, 552-68	17
670	Compensatory angiogenesis and tumor refractoriness. 2015 , 4, e153	67
669	Role of environmental chemicals, processed food derivatives, and nutrients in the induction of carcinogenesis. 2015 , 24, 2337-52	9
668	Introduction. 2015 , 1-6	1
667	Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms. 2015 , 16, 459-71	150
666	Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer. 2015 , 47, 359-69	41
665	Integrative Analysis Identifies Transcription Factor-DNA Methylation Relationships and Introduces New Avenues for Translating Cancer Epigenetics into the Clinic. 2015 , 211-228	
664	Cross-species oncogenomics using zebrafish models of cancer. 2015 , 30, 73-9	9
663	Genomic Predictors of Outcome in Prostate Cancer. 2015 , 68, 1033-44	136
662	Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells. 2015 , 361, 86-96	38
661	Glioblastoma stem cells (GSCs) epigenetic plasticity and interconversion between differentiated non-GSCs and GSCs. 2015 , 2, 152-163	124
660	C8orf4 negatively regulates self-renewal of liver cancer stem cells via suppression of NOTCH2 signalling. 2015 , 6, 7122	86
659	Epigenetic therapy for solid tumors: from bench science to clinical trials. 2015 , 7, 215-35	46
658	Next Generation Sequencing in Cancer Research, Volume 2. 2015 ,	4

657	Tumor twitter: cellular communication in the breast cancer stem cell niche. 2015 , 5, 469-71	20
656	Overview of the "epigenetic end points in toxicologic pathology and relevance to human health" session of the 2014 Society Of Toxicologic Pathology Annual Symposium. 2015 , 43, 98-100	1
655	Genetic alterations of DNA methylation machinery in human diseases. 2015 , 7, 247-65	156
654	The long noncoding RNA lncTCF7 promotes self-renewal of human liver cancer stem cells through activation of Wnt signaling. 2015 , 16, 413-25	437
653	Development of a Fluorescent Reporter System to Delineate Cancer Stem Cells in Triple-Negative Breast Cancer. 2015 , 33, 2114-2125	53
652	Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. 2015 , 15, 302-10	227
651	Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors. 2015 , 361, 197-206	8
650	Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment. 2015 , 36, 1219-27	103
649	Identification of the specific epigenetic alterations associated with chemo-resistance via reprogramming of cancer cells. 2015 , 85, 710-4	1
648	Application of Evolutionary Principles to Cancer Therapy. 2015 , 75, 4675-80	74
647	VEGF-mediated cell survival in non-small-cell lung cancer: implications for epigenetic targeting of VEGF receptors as a therapeutic approach. 2015 , 7, 897-910	7
646	LIFR functions as a metastasis suppressor in hepatocellular carcinoma by negatively regulating phosphoinositide 3-kinase/AKT pathway. 2015 , 36, 1201-12	44
645	Biology in Stem Cell Niche. 2015 ,	
644	Epigenetic and Immune Regulation of Colorectal Cancer Stem Cells. 2015 , 11, 414-421	4
643	Genetic Testing and Tissue Banking for Personalized Oncology: Analytical and Institutional Factors. 2015 , 42, 713-23	10
642	Maspin Expression in Prostate Tumor Cells Averts Stemness and Stratifies Drug Sensitivity. 2015 , 75, 3970-9	15
641	The DNA Methyltransferase DNMT1 and Tyrosine-Protein Kinase KIT Cooperatively Promote Resistance to 5-Aza-2Pdeoxycytidine (Decitabine) and Midostaurin (PKC412) in Lung Cancer Cells. 2015 , 290, 18480-94	23
640	DREAMing: a simple and ultrasensitive method for assessing intratumor epigenetic heterogeneity directly from liquid biopsies. 2015 , 43, e154	32

639	Pulmonary Metastases Exhibit Epigenetic Clonality: Implications for Precision Cancer Therapy. 2015 , 100, 1839-48; discussion 1848	4
638	Cell death mechanisms of plant-derived anticancer drugs: beyond apoptosis. 2015 , 20, 1531-62	181
637	Designing a broad-spectrum integrative approach for cancer prevention and treatment. 2015 , 35 Suppl, S276-S304	179
636	Additive impact of HER2-/PTK6-RNAi on interactions with HER3 or IGF-1R leads to reduced breast cancer progression in vivo. 2015 , 9, 282-94	10
635	Inhibition of the colony-stimulating-factor-1 receptor affects the resistance of lung cancer cells to cisplatin. 2016 , 7, 56408-56421	19
634	Personalized Epigenetics. 2016 , 843-858	2
633	Practical aspects of NGS-based pathways analysis for personalized cancer science and medicine. 2016 , 7, 52493-52516	11
632	Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells. 2016 , 7, 34084-99	127
631	Cancer Stem Cells: Cellular Plasticity, Niche, and its Clinical Relevance. 2016 , 6,	61
630	New Progress of Epigenetic Biomarkers in Urological Cancer. 2016 , 2016, 9864047	19
629	MicroRNA-200c delivered by solid lipid nanoparticles enhances the effect of paclitaxel on breast cancer stem cell. 2016 , 11, 6713-6725	55
628	Melanoma-Derived BRAF(V600E) Mutation in Peritumoral Stromal Cells: Implications for in Vivo Cell Fusion. 2016 , 17,	10
627	Long Noncoding RNA lncCAMTA1 Promotes Proliferation and Cancer Stem Cell-Like Properties of Liver Cancer by Inhibiting CAMTA1. 2016 , 17,	48
626	Single-cell profiling approaches to probing tumor heterogeneity. 2016 , 139, 243-55	42
625	Epigenetic Pharmacology. 2016 , 1-25	
624	Sensitivity of GBM cells to cAMP agonist-mediated apoptosis correlates with CD44 expression and agonist resistance with MAPK signaling. 2016 , 7, e2494	19
623	A model of phenotypic state dynamics initiates a promising approach to control heterogeneous malignant cell populations. 2016 ,	4
622	The cause of cancer mutations: Improvable bad life or inevitable stochastic replication errors?. 2016 , 50, 799-811	6

621	The physics of cancer: The role of epigenetics and chromosome conformation in cancer progression. 2016,	4
620	Cancer stem cells: understanding tumor hierarchy and heterogeneity. 2016, 95, S2-S7	118
619	Mechanistic insight into the aberrant silencing of the keratin 13 gene in oral squamous cell carcinoma cells. 2016, 58, 45-49	0
618	Intra-tumour heterogeneity - going beyond genetics. 2016, 283, 2245-58	50
617	DNA methylation by DNMT1 and DNMT3b methyltransferases is driven by the MUC1-C oncoprotein in human carcinoma cells. 2016, 35, 6439-6445	51
616	Epigenetic Determinants of Cancer. 2016, 8,	501
615	The overshoot and phenotypic equilibrium in characterizing cancer dynamics of reversible phenotypic plasticity. 2016, 390, 40-9	5
614	Low-dose DNA-demethylating agent enhances the chemosensitivity of cancer cells by targeting cancer stem cells via the upregulation of microRNA-497. 2016, 142, 1431-9	12
613	Self-renewal of tumor cells: epigenetic determinants of the cancer stem cell phenotype. 2016, 36, 92-9	17
612	The Greater Genomic Landscape: The Heterogeneous Evolution of Cancer. 2016, 76, 5605-5609	19
611	Micro-Environmental Stress Induces Src-Dependent Activation of Invadopodia and Cell Migration in Ewing Sarcoma. 2016, 18, 480-8	16
610	Cbx8 Acts Non-canonically with Wdr5 to Promote Mammary Tumorigenesis. 2016, 16, 472-486	63
609	The linker histone H1.0 generates epigenetic and functional intratumor heterogeneity. 2016, 353,	101
608	Epigenetic control of the tumor microenvironment. 2016, 8, 1671-1687	49
607	G9a/RelB regulates self-renewal and function of colon-cancer-initiating cells by silencing Let-7b and activating the K-RAS/βcatenin pathway. 2016, 18, 993-1005	19
606	Colorectal Cancer Stem Cells. 2016, 177-209	
605	scan_tcga tools for integrated epigenomic and transcriptomic analysis of tumor subgroups. 2016, 8, 1315-1330	11
604	Investigation of EZH2 pathways for novel epigenetic treatment strategies in oropharyngeal cancer. 2016, 45, 54	13

603	Putative RNA-directed adaptive mutations in cancer evolution. 2016 , 7, 164-187	5
602	Heterogeneity of Cancer Stem Cells: Rationale for Targeting the Stem Cell Niche. 2016 , 1866, 276-289	34
601	Progress in Cancer Immunotherapy. 2016 ,	5
600	Chromatin Remodeling Factor LSH Drives Cancer Progression by Suppressing the Activity of Fumarate Hydratase. 2016 , 76, 5743-5755	69
599	New strategy to address DNA-methyl transferase activity in ovarian cancer cell cultures by monitoring the formation of 5-methylcytosine using HPLC-UV. 2016 , 1028, 16-24	9
598	ChIP-seq in studying epigenetic mechanisms of disease and promoting precision medicine: progresses and future directions. 2016 , 8, 1239-58	16
597	Cell population heterogeneity and evolution towards drug resistance in cancer: Biological and mathematical assessment, theoretical treatment optimisation. 2016 , 1860, 2627-45	45
596	DNA Methylation in Cancer and Aging. 2016 , 76, 3446-50	398
595	Global histone modification profiling reveals the epigenomic dynamics during malignant transformation in a four-stage breast cancer model. 2016 , 8, 34	50
594	DNA methylation dynamics in cellular commitment and differentiation. 2016 , 15, 443-453	35
593	Role of Pericellular Matrix in the Regulation of Cancer Stemness. 2016 , 12, 464-75	17
592	Metabolic Reprogramming and Dependencies Associated with Epithelial Cancer Stem Cells Independent of the Epithelial-Mesenchymal Transition Program. 2016 , 34, 1163-76	64
591	Hypermethylation reduces the expression of PNPLA7 in hepatocellular carcinoma. 2016 , 12, 670-674	7
590	Long non-coding RNA DILC regulates liver cancer stem cells via IL-6/STAT3 axis. 2016 , 64, 1283-94	200
589	Imaging tumour cell heterogeneity following cell transplantation into optically clear immune-deficient zebrafish. 2016 , 7, 10358	62
588	Complement proteins C7 and CFH control the stemness of liver cancer cells via LSF-1. 2016 , 372, 24-35	28
587	Conversion to stem-cell state in response to microenvironmental cues is regulated by balance between epithelial and mesenchymal features in lung cancer cells. 2016 , 10, 253-71	77
586	Identification and optimization of hydrazone-gallate derivatives as specific inhibitors of DNA methyltransferase 3A. 2016 , 8, 373-80	9

585	Therapeutic strategies targeting cancer stem cells. 2016 , 107, 5-11	159
584	Promises and pitfalls for recombinant oligoclonal antibodies-based therapeutics in cancer and infectious disease. 2016 , 40, 51-61	10
583	Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer. 2016 , 16, 541-51	3
582	Enhancer methylation dynamics contribute to cancer plasticity and patient mortality. 2016 , 26, 601-11	67
581	What are we expecting from PET/MRI?. 2016 , 40, 31-40	1
580	A study of the role of Notch1 and JAG1 gene methylation in development of breast cancer. 2016 , 33, 35	11
579	HBXIP and LSD1 Scaffolded by lncRNA Hotair Mediate Transcriptional Activation by c-Myc. 2016 , 76, 293-304	85
578	Promoting tumor penetration of nanoparticles for cancer stem cell therapy by TGF- β signaling pathway inhibition. 2016 , 82, 48-59	81
577	Epigenetics in Personalized Management of Lung Cancer. 2016 , 890, 111-22	13
576	MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness-Promoting Chromatin Modifications Independent of p53. <i>Molecular Cell</i> , 2016 , 61, 68-83	17.6 67
575	Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management. 2016 ,	1
574	The Methylated DNA Immunoprecipitation [MeDIP] to Investigate the Epigenetic Remodeling in Cell Fate Determination and Cancer Development. 2016 , 1379, 69-76	2
573	Preface. 2016 , 1379, v	
572	Inflammation-induced epigenetic switches in cancer. 2016 , 73, 23-39	34
571	The complexity of epigenetic diseases. 2016 , 238, 333-44	21
570	MacroH2A1 downregulation enhances the stem-like properties of bladder cancer cells by transactivation of Lin28B. 2016 , 35, 1292-301	29
569	Stress granule-associated protein G3BP2 regulates breast tumor initiation. 2017 , 114, 1033-1038	42
568	Oral Biosciences: The annual review 2016. 2017 , 59, 1-5	2

567	Nuclear factor one transcription factors as epigenetic regulators in cancer. 2017 , 140, 2634-2641	32
566	Epigenetics in cancer stem cells. 2017 , 16, 29	195
565	Recent progress in single-cell cancer genomics. 2017 , 42, 22-32	41
564	Critical threshold levels of DNA methyltransferase 1 are required to maintain DNA methylation across the genome in human cancer cells. 2017 , 27, 533-544	44
563	PLMET: A Novel Pseudolikelihood-Based EM Test for Homogeneity in Generalized Exponential Tilt Mixture Models. 2017 , 112, 1393-1404	6
562	Acquired Resistance with Epigenetic Alterations Under Long-Term Antiangiogenic Therapy for Hepatocellular Carcinoma. 2017 , 16, 1155-1165	18
561	Gene expression profiling of circulating CD133 cells of hepatocellular carcinoma patients associated with HCV infection. 2017 , 29, 19-24	6
560	Knockdown of linc-OIP5 inhibits proliferation and migration of glioma cells through down-regulation of YAP-NOTCH signaling pathway. 2017 , 610, 24-31	36
559	The evolving concept of cancer stem-like cells in thyroid cancer and other solid tumors. 2017 , 97, 1142-1151	37
558	Review: Regulation of the cancer epigenome by long non-coding RNAs. 2017 , 407, 106-112	71
557	EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. 2017 , 14, 611-629	1172
556	Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4 oncogenic axis in multiple myeloma. 2017 , 108, 641-652	23
555	Image-guided genomics of phenotypically heterogeneous populations reveals vascular signalling during symbiotic collective cancer invasion. 2017 , 8, 15078	56
554	Inhibition of PRDM14 expression in pancreatic cancer suppresses cancer stem-like properties and liver metastasis in mice. 2017 , 38, 638-648	29
553	DNA methylation in the tumor microenvironment. 2017 , 18, 365-372	18
552	Cell state plasticity, stem cells, EMT, and the generation of intra-tumoral heterogeneity. 2017 , 3, 14	77
551	Murine melanoma cells incomplete reprogramming using non-viral vector. 2017 , 50,	5
550	Extracellular vesicles in the tumor microenvironment: Therapeutic resistance, clinical biomarkers, and targeting strategies. 2017 , 37, 1318-1349	30

549	Epigenetic effects of inhibition of heat shock protein 90 (HSP90) in human pancreatic and colon cancer. 2017 , 402, 110-116	16
548	Reprogramming of the Tumor in the Hypoxic Niche: The Emerging Concept and Associated Therapeutic Strategies. 2017 , 38, 669-686	94
547	Homeostasis Back and Forth: An Ecoevolutionary Perspective of Cancer. 2017 , 7,	31
546	Perturbed Signaling and Role of Posttranslational Modifications in Cancer Drug Resistance. 2017 , 483-510	2
545	The new frontier of epigenetic heterogeneity in B-cell neoplasms. 2017 , 24, 402-408	9
544	Drug Resistance in Bacteria, Fungi, Malaria, and Cancer. 2017 ,	9
543	Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer. 2017 , 40, 105-118	35
542	Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. 2017 , 20, 233-246.e7	235
541	Cancer as an ecomolecular disease and a neoplastic consortium. 2017 , 1868, 484-499	9
540	The Molecular Basis of DNA Demethylation. 2017 , 53-73	
539	Chronic Cigarette Smoke-Induced Epigenomic Changes Precede Sensitization of Bronchial Epithelial Cells to Single-Step Transformation by KRAS Mutations. 2017 , 32, 360-376.e6	116
538	Smoke-Induced Changes to the Epigenome Provide Fertile Ground for Oncogenic Mutation. 2017 , 32, 278-280	11
537	The Role of Axl Receptor Tyrosine Kinase in Tumor Cell Plasticity and Therapy Resistance. 2017 , 351-376	2
536	Breast Cancer Spheroids Reveal a Differential Cancer Stem Cell Response to Chemotherapeutic Treatment. 2017 , 7, 10382	73
535	No patient left behind: The promise of immune priming with epigenetic agents. 2017 , 6, e1315486	10
534	HDAC1 Upregulation by NANOG Promotes Multidrug Resistance and a Stem-like Phenotype in Immune Edited Tumor Cells. 2017 , 77, 5039-5053	57
533	Epigenetic plasticity and the hallmarks of cancer. 2017 , 357,	551
532	Reprogramming to developmental plasticity in cancer stem cells. 2017 , 430, 266-274	26

531	Epigenomic analysis in a cell-based model reveals the roles of H3K9me3 in breast cancer transformation. 2017 , 9, 1077-1092	6
530	The Expression of Connexins and SOX2 Reflects the Plasticity of Glioma Stem-Like Cells. 2017 , 10, 555-569	13
529	An autocrine inflammatory forward-feedback loop after chemotherapy withdrawal facilitates the repopulation of drug-resistant breast cancer cells. 2017 , 8, e2932	55
528	Exosomes from metastatic cancer cells transfer amoeboid phenotype to non-metastatic cells and increase endothelial permeability: their emerging role in tumor heterogeneity. 2017 , 7, 4711	58
527	EphA2 and ephrin-A5 are not a receptor-ligand pair in the ocular lens. 2017 , 162, 9-17	9
526	Antagonizing miR-455-3p inhibits chemoresistance and aggressiveness in esophageal squamous cell carcinoma. 2017 , 16, 106	53
525	At the crossroads of cancer stem cells and targeted therapy resistance. 2017 , 385, 87-96	19
524	Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance. 2017 , 64, 107-115	45
523	Role of epigenetics in lung cancer heterogeneity and clinical implication. 2017 , 64, 18-25	32
522	Defining, distinguishing and detecting the contribution of heterogeneous methylation to cancer heterogeneity. 2017 , 64, 5-17	12
521	Methylation modification in gastric cancer and approaches to targeted epigenetic therapy (Review). 2017 , 50, 1921-1933	19
520	Modulation of DNA methylation by human papillomavirus E6 and E7 oncoproteins in cervical cancer. 2018 , 15, 11-22	31
519	Epigenetic Modifications and Head and Neck Cancer: Implications for Tumor Progression and Resistance to Therapy. 2017 , 18,	80
518	Cancer Epigenetics. 2017 , 519-534	1
517	Stemness in Cancer: Stem Cells, Cancer Stem Cells, and Their Microenvironment. 2017 , 2017, 5619472	159
516	Editorial: Cancer Epigenetics. 2018 , 18, 3-4	6
515	The Response of Cancer Cell Populations to Therapies. 2017 , 137-152	
514	Bladder cancer stem cells: clonal origin and therapeutic perspectives. 2017 , 8, 66668-66679	49

513	Metabolomic mapping of cancer stem cells for reducing and exploiting tumor heterogeneity. 2017 , 8, 99223-99236	8
512	Highlights from the Literature. 2017 , 19, 611-613	78
511	Tumor Heterogeneity. 2017 , 37-55	4
510	The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML. 2018 , 37, 2687-2701	42
509	Phase Ib/II study of safety and efficacy of low-dose decitabine-primed chemoimmunotherapy in patients with drug-resistant relapsed/refractory alimentary tract cancer. 2018 , 143, 1530-1540	15
508	Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors. 2018 , 78, 3350-3362	23
507	Sarcoma-The standard-bearer in cancer discovery. 2018 , 126, 1-5	19
506	Rapid Contour-based Segmentation for F-FDG PET Imaging of Lung Tumors by Using ITK-SNAP: Comparison to Expert-based Segmentation. 2018 , 288, 277-284	14
505	Cripto-1 contributes to stemness in hepatocellular carcinoma by stabilizing Dishevelled-3 and activating Wnt/ β -catenin pathway. 2018 , 25, 1426-1441	30
504	Redundant angiogenic signaling and tumor drug resistance. 2018 , 36, 47-76	69
503	Intratumor heterogeneity in epigenetic patterns. 2018 , 51, 12-21	34
502	AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis. 2018 , 9, 222	34
501	Methylation profiling identifies two subclasses of squamous cell carcinoma related to distinct cells of origin. 2018 , 9, 577	42
500	DNA Methylation Patterns Separate Senescence from Transformation Potential and Indicate Cancer Risk. 2018 , 33, 309-321.e5	49
499	Synthetic strigolactone analogues reveal anti-cancer activities on hepatocellular carcinoma cells. 2018 , 28, 1077-1083	16
498	Antiestrogen Therapy Increases Plasticity and Cancer Stemness of Prolactin-Induced ER α Mammary Carcinomas. 2018 , 78, 1672-1684	13
497	Effects of early-life malnutrition on neurodevelopment and neuropsychiatric disorders and the potential mechanisms. 2018 , 83, 64-75	40
496	The impact of non-genetic heterogeneity on cancer cell death. 2018 , 53, 99-114	28

495	HDACis (class I), cancer stem cell, and phytochemicals: Cancer therapy and prevention implications. 2018 , 97, 1445-1453	28
494	Pan-HDAC inhibition by panobinostat mediates chemosensitization to carboplatin in non-small cell lung cancer via attenuation of EGFR signaling. 2018 , 417, 152-160	55
493	CHD4-mediated loss of E-cadherin determines metastatic ability in triple-negative breast cancer cells. 2018 , 363, 65-72	17
492	The depalmitoylase APT1 directs the asymmetric partitioning of Notch and Wnt signaling during cell division. 2018 , 11,	9
491	Translational control of aberrant stress responses as a hallmark of cancer. 2018 , 244, 650-666	41
490	Bitter melon juice exerts its efficacy against pancreatic cancer via targeting both bulk and cancer stem cells. 2018 , 57, 1166-1180	8
489	Toward understanding of the role of reversibility of phenotypic switching in the evolution of resistance to therapy. 2018 , 382, 1586-1600	3
488	Epigenetic Pharmacology. 2018 , 1551-1575	
487	EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours. 2018 , 37, 4073-4093	15
486	Establishment of a high-throughput detection system for DNA demethylating agents. 2018 , 13, 147-155	8
485	The Evolution and Ecology of Resistance in Cancer Therapy. 2018 , 8,	81
484	The Dual Role of Bone Morphogenetic Proteins in Cancer. 2018 , 8, 1-13	90
483	Downregulation of DNMT3A by miR-708-5p Inhibits Lung Cancer Stem Cell-like Phenotypes through Repressing Wnt/ β -catenin Signaling. 2018 , 24, 1748-1760	52
482	Epigenetics in pediatric acute lymphoblastic leukemia. 2018 , 51, 129-138	26
481	Functionalised nanomaterials for eradication of CSCs, a promising approach for overcoming tumour heterogeneity. 2018 , 26, 649-657	7
480	Lineage Plasticity in Cancer Progression and Treatment. 2018 , 2, 271-289	37
479	Cyclodipeptide c(Orn-Pro) Conjugate with 4-Ethylpiperic Acid Abrogates Cancer Cell Metastasis through Modulating MDM2. 2018 , 29, 164-175	5
478	Modulating secreted components of tumor microenvironment: A masterstroke in tumor therapeutics. 2018 , 19, 3-12	30

477	Oral Cancer: Genetics and the Role of Precision Medicine. 2018 , 62, 29-46	25
476	Clinical Utility of promoter methylation of the tumor suppressor genes DKK3, and RASSF1A in breast cancer patients. 2018 , 19, 87-90	1
475	Reversal of docetaxel resistance in prostate cancer by Notch signaling inhibition. 2018 , 29, 871-879	17
474	MicroRNA-486-5p functions as a tumor suppressor of proliferation and cancer stem-like cell properties by targeting Sirt1 in liver cancer. 2019 , 41, 1938-1948	15
473	Digital High-Resolution Melt Platform for Rapid and Parallelized Molecule-by-Molecule Genetic Profiling. 2018 , 2018, 5342-5345	
472	Amphiphilic Drug Conjugates as Nanomedicines for Combined Cancer Therapy. 2018 , 29, 3967-3981	37
471	Epigenetic Heterogeneity in Human Colorectal Tumors Reveals Preferential Conservation And Evidence of Immune Surveillance. 2018 , 8, 17292	11
470	A Microwell-Assisted Multiaptamer Immunomagnetic Platform for Capture and Genetic Analysis of Circulating Tumor Cells. 2018 , 7, e1801231	25
469	miR-200c/141 Regulates Breast Cancer Stem Cell Heterogeneity via Targeting HIPK1/βCatenin Axis. 2018 , 8, 5801-5813	42
468	Sensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy. 2018 , 10,	82
467	Linking single-cell measurements of mass, growth rate, and gene expression. 2018 , 19, 207	31
466	The role of cancer stem cells in the modulation of anti-tumor immune responses. 2018 , 53, 189-200	48
465	Facile profiling of molecular heterogeneity by microfluidic digital melt. 2018 , 4, eaat6459	21
464	Chondrosarcoma: An overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targets. 2018 , 131, 102-109	38
463	Biomarkers: paving stones on the road towards the personalized precision medicine for oral squamous cell carcinoma. 2018 , 18, 911	15
462	Joint single-cell DNA accessibility and protein epitope profiling reveals environmental regulation of epigenomic heterogeneity. 2018 , 9, 4590	41
461	Human endogenous retroviruses role in cancer cell stemness. 2018 , 53, 17-30	30
460	Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets. 2018 , 9, 427	64

459	Whole-Genome Sequencing Reveals Elevated Tumor Mutational Burden and Initiating Driver Mutations in African Men with Treatment-Naïve, High-Risk Prostate Cancer. 2018 , 78, 6736-6746	36
458	Carbonic Anhydrase IX-Targeted Near-Infrared Dye for Fluorescence Imaging of Hypoxic Tumors. 2018 , 29, 3320-3331	12
457	Strigolactones-a novel class of phytohormones as anti-cancer agents. 2018 , 43, 168-172	5
456	A microfluidic device for isolating intact chromosomes from single mammalian cells and probing their folding stability by controlling solution conditions. 2018 , 8, 13684	5
455	Hypoxia-inducible KDM3A addiction in multiple myeloma. 2018 , 2, 323-334	33
454	Nanogel-mediated delivery of a cocktail of epigenetic drugs plus doxorubicin overcomes drug resistance in breast cancer cells. 2018 , 8, 1289-1299	7
453	High collagen density augments mTOR-dependent cancer stem cells in ER ⁺ mammary carcinomas, and increases mTOR-independent lung metastases. 2018 , 433, 1-9	16
452	Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer. 2018 , 17, 258-273	29
451	Role of RNF20 in cancer development and progression - a comprehensive review. 2018 , 38,	19
450	Hypoxia Promotes Resistance to EGFR Inhibition in NSCLC Cells via the Histone Demethylases, LSD1 and PLU-1. 2018 , 16, 1458-1469	38
449	Detection of the Cell Cycle-Regulated Negative Feedback Phosphorylation of Mitogen-Activated Protein Kinases in Breast Carcinoma using Nanofluidic Proteomics. 2018 , 8, 9991	7
448	From Chemotherapy to Combined Targeted Therapeutics: and Models to Decipher Intra-tumor Heterogeneity. 2018 , 9, 77	14
447	Deciphering mechanisms of brain metastasis in melanoma - the gist of the matter. 2018 , 17, 106	26
446	Development of Neuroendocrine Prostate Cancers by the Ser/Arg Repetitive Matrix 4-Mediated RNA Splicing Network. 2018 , 8, 93	11
445	Oncolytic Virotherapy versus Cancer Stem Cells: A Review of Approaches and Mechanisms. 2018 , 10,	24
444	Epigenetics and MicroRNAs in Cancer. 2018 , 19,	94
443	Prolonged inhibition of class I PI3K promotes liver cancer stem cell expansion by augmenting SGK3/GSK-3 β /E-catenin signalling. 2018 , 37, 122	10
442	Metabolic recoding of epigenetics in cancer. 2018 , 38, 25	48

441	Microenvironmental Signals and Biochemical Information Processing: Cooperative Determinants of Intratumoral Plasticity and Heterogeneity. 2018 , 6, 44	22
440	New insights from the widening homogeneity perspective to target intratumor heterogeneity. 2018 , 38, 17	6
439	Unsolvable Problems of Biology: It Is Impossible to Create Two Identical Organisms, to Defeat Cancer, or to Map Organisms onto Their Genomes. 2018 , 83, 370-380	4
438	Stabilization of HDAC1 via TCL1-pAKT-CHFR axis is a key element for NANOG-mediated multi-resistance and stem-like phenotype in immune-edited tumor cells. 2018 , 503, 1812-1818	8
437	Under explored epigenetic modulators: role in glioma chemotherapy. 2018 , 833, 201-209	2
436	Defective DNA Methylation/Demethylation Processes Define Aging-Dependent Methylation Patterns. 2018 , 33-58	
435	BRN2, a POUerful driver of melanoma phenotype switching and metastasis. 2019 , 32, 9-24	35
434	CT texture analysis of pancreatic cancer. 2019 , 29, 1067-1073	68
433	Near-physiological microenvironment simulation on chip to evaluate drug resistance of different loci in tumour mass. 2019 , 191, 67-73	10
432	Current Applications for Overcoming Resistance to Targeted Therapies. 2019 ,	1
431	Branched-Chain Amino Acid Metabolic Reprogramming Orchestrates Drug Resistance to EGFR Tyrosine Kinase Inhibitors. 2019 , 28, 512-525.e6	32
430	Ursolic Acid Inhibits Epithelial-Mesenchymal Transition through the Axl/NF-B Pathway in Gastric Cancer Cells. 2019 , 2019, 2474805	6
429	Key actors in cancer therapy: epigenetic modifiers. 2019 , 43, 155-170	3
428	Therapies to Overcome Multidrug-Resistant Receptors. 2019 , 131-159	1
427	Multi-omic Dissection of Oncogenically Active Epiproteomes Identifies Drivers of Proliferative and Invasive Breast Tumors. 2019 , 17, 359-378	2
426	Interplay of Darwinian Selection, Lamarckian Induction and Microvesicle Transfer on Drug Resistance in Cancer. 2019 , 9, 9332	15
425	Cell signaling and cancer: a mechanistic insight into drug resistance. 2019 , 46, 5645-5659	31
424	Single-Cell Analysis of Circulating Tumor Cells: How Far Have We Come in the -Omics Era?. 2019 , 10, 958	29

423	SIRT1 in the Development and Treatment of Hepatocellular Carcinoma. 2019 , 6, 148	24
422	The Histone Demethylase LSD1/DM1A Mediates Chemoresistance in Breast Cancer via Regulation of a Stem Cell Program. 2019 , 11,	24
421	ALDH1A2 Is a Candidate Tumor Suppressor Gene in Ovarian Cancer. 2019 , 11,	8
420	Epigenetic heterogeneity in cancer. 2019 , 7, 23	73
419	EBV-miR-BART7-3p Imposes Stemness in Nasopharyngeal Carcinoma Cells by Suppressing SMAD7. 2019 , 10, 939	16
418	Identification of CHD4- β integrin axis as a prognostic marker in triple-negative breast cancer using next-generation sequencing and bioinformatics. 2019 , 238, 116963	9
417	Digital DNA Sequence Profiling of Rare Epigenetic Cancer Biomarkers in A Highly Parallelized Microfluidic Platform. 2019 ,	
416	Mechanisms and Implications of Metabolic Heterogeneity in Cancer. 2019 , 30, 434-446	159
415	Mitochondrial fission promotes self-renewal and tumorigenic potential in prostate cancer. 2019 , 6, e1644598	2
414	The invasion of de-differentiating cancer cells into hierarchical tissues. 2019 , 15, e1007167	9
413	Novel Heat Shock Protein 90 Inhibitors Suppress P-Glycoprotein Activity and Overcome Multidrug Resistance in Cancer Cells. 2019 , 20,	9
412	Targeting epigenetic machinery: Emerging novel allosteric inhibitors. 2019 , 204, 107406	17
411	Towards precision oncology in advanced prostate cancer. 2019 , 16, 645-654	72
410	Trends and Challenges in Tumor Anti-Angiogenic Therapies. 2019 , 8,	78
409	Microfluidic modelling of the tumor microenvironment for anti-cancer drug development. 2019 , 19, 369-386	112
408	Metabolic Intermediates in Tumorigenesis and Progression. 2019 , 15, 1187-1199	11
407	Targeted Therapies for Lung Cancer. 2019 ,	
406	Connections between metabolism and epigenetics in cancers. 2019 , 57, 52-58	52

405	Bibliography. 2019 , 489-533	
404	Extrachromosomal circular DNAs: an extra piece of evidence to depict tumor heterogeneity. 2019 , 5, FSO390	14
403	Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study). 2019 , 60, 2143-2151	9
402	Theranostics in Interventional Oncology: Versatile Carriers for Diagnosis and Targeted Image-Guided Minimally Invasive Procedures. 2019 , 10, 450	15
401	Epigenetic Control of Mitochondrial Fission Enables Self-Renewal of Stem-like Tumor Cells in Human Prostate Cancer. 2019 , 30, 303-318.e6	32
400	Landscape perspectives of tumor, EMT, and development. 2019 , 16, 051003	4
399	UHRF1 depletion and HDAC inhibition reactivate epigenetically silenced genes in colorectal cancer cells. 2019 , 11, 70	11
398	DNA methylation of shelf, shore and open sea CpG positions distinguish high microsatellite instability from low or stable microsatellite status colon cancer stem cells. 2019 , 11, 587-604	12
397	Contribution of Epithelial Plasticity to Therapy Resistance. 2019 , 8,	26
396	Commonly integrated epigenetic modifications of differentially expressed genes lead to adaptive resistance in cancer. 2019 , 11, 732-737	8
395	Transcriptional Reprogramming and Novel Therapeutic Approaches for Targeting Prostate Cancer Stem Cells. 2019 , 9, 385	7
394	Multiscale modeling reveals angiogenesis-induced drug resistance in brain tumors and predicts a synergistic drug combination targeting EGFR and VEGFR pathways. 2019 , 20, 203	8
393	Engineering Multidimensional Evolutionary Forces to Combat Cancer. 2019 , 9, 587-604	10
392	Exosomes, metastases, and the miracle of cancer stem cell markers. 2019 , 38, 259-295	26
391	Rbfox2 dissociation from stress granules suppresses cancer progression. 2019 , 51, 1-12	17
390	Synthesis and characterizations of Ag-decorated graphene oxide nanosheets and their cytotoxicity studies. 2019 , 73, 1945-1952	9
389	Deregulated GATA6 modulates stem cell-like properties and metabolic phenotype in hepatocellular carcinoma. 2019 , 145, 1860-1873	9
388	miR-128-3p inhibits glioma cell proliferation and differentiation by targeting NPTX1 through IRS-1/PI3K/AKT signaling pathway. 2019 , 17, 2921-2930	23

387	On fitness: how do mutations shape the biology of cancer?. 2019 , 47, 559-569	1
386	Modeling differentiation-state transitions linked to therapeutic escape in triple-negative breast cancer. 2019 , 15, e1006840	9
385	Multi-modality in gene regulatory networks with slow promoter kinetics. 2019 , 15, e1006784	18
384	Molecular insights into cancer drug resistance from a proteomics perspective. 2019 , 16, 413-429	12
383	Cancer epigenetics in solid organ tumours: A primer for surgical oncologists. 2019 , 45, 736-746	12
382	Broad antifungal resistance mediated by RNAi-dependent epimutation in the basal human fungal pathogen <i>Mucor circinelloides</i> . 2019 , 15, e1007957	25
381	Aging-like Spontaneous Epigenetic Silencing Facilitates Wnt Activation, Stemness, and Braf-Induced Tumorigenesis. 2019 , 35, 315-328.e6	64
380	Hyaluronan-mediated motility receptor confers resistance to chemotherapy TGF β /Smad2-induced epithelial-mesenchymal transition in gastric cancer. 2019 , 33, 6365-6377	32
379	DNA methylation as the most important content of epigenetics in traditional Chinese herbal medicine. 2019 , 13, 357-369	9
378	Intracellular Energy Variability Modulates Cellular Decision-Making Capacity. 2019 , 9, 20196	6
377	Cross-Talk Between circRNAs and mRNAs Modulates MiRNA-mediated Circuits and Affects Melanoma Plasticity. 2019 , 12, 95-104	11
376	The CTLH Complex in Cancer Cell Plasticity. 2019 , 2019, 4216750	10
375	Phosphorylation of the histone demethylase KDM5B and regulation of the phenotype of triple negative breast cancer. 2019 , 9, 17663	11
374	The Cross Talk between Cancer Stem Cells/Cancer Initiating Cells and Tumor Microenvironment: The Missing Piece of the Puzzle for the Efficient Targeting of these Cells with Immunotherapy. 2019 , 12, 133-148	20
373	Application of Single-Cell Omics in Breast Cancer. 2019 , 69-103	4
372	LSD1/KDM1A, a Gate-Keeper of Cancer Stemness and a Promising Therapeutic Target. 2019 , 11,	32
371	Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. 2019 , 4, 62	284
370	Cancer Stem Cells and Osteosarcoma: Opportunities and Limitations. 2019 , 34, 275-286	

369	Ovarian cancer stem cells: What progress have we made?. 2019 , 107, 92-103	26
368	Time to abandon single-site irradiation for inducing abscopal effects. 2019 , 16, 123-135	127
367	Knockdown of long non-coding RNA linc-ITGB1 inhibits cancer stemness and epithelial-mesenchymal transition by reducing the expression of Snail in non-small cell lung cancer. 2019 , 10, 128-136	17
366	TROY expression is associated with pathological stage and poor prognosis in patients treated with radical cystectomy. 2019 , 24, 91-96	3
365	Metabolism and epigenetics of pancreatic cancer stem cells. 2019 , 57, 19-26	27
364	Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia. 2019 , 33, 931-944	25
363	Epigenetic polypharmacology: A new frontier for epi-drug discovery. 2020 , 40, 190-244	49
362	The emerging role of epigenetic therapeutics in immuno-oncology. 2020 , 17, 75-90	116
361	Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise. 2020 , 17, 91-107	142
360	In Silico implementation of evolutionary paradigm in therapy design: Towards anti-cancer therapy as Darwinian process. 2020 , 485, 110038	0
359	Tumor Liquid Biopsies. 2020 ,	5
358	Tumor dormancy as an alternative step in the development of chemoresistance and metastasis - clinical implications. 2020 , 43, 155-176	20
357	Downregulation of FOXO3a by DNMT1 promotes breast cancer stem cell properties and tumorigenesis. 2020 , 27, 966-983	30
356	Insights into new mechanisms and models of cancer stem cell multidrug resistance. 2020 , 60, 166-180	85
355	Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion. 2020 , 60, 351-361	47
354	A multicenter analysis of genomic profiles and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the lung. 2020 , 33, 626-638	20
353	LncRNA-cCSC1 modulates cancer stem cell properties in colorectal cancer via activation of the Hedgehog signaling pathway. 2020 , 121, 2510-2524	28
352	Investigating Tumor Heterogeneity in Mouse Models. 2020 , 4, 99-119	15

351	Disordered chromatin packing regulates phenotypic plasticity. 2020 , 6, eaax6232	17
350	Interweaving Tumor Heterogeneity into the Cancer Epigenetic/Metabolic Axis. 2020 , 33, 946-965	2
349	The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. 2020 , 20, 158-173	74
348	Cracking the context-specific PI3K signaling code. 2020 , 13,	23
347	Current discovery strategies for hepatocellular carcinoma therapeutics. 2020 , 15, 243-258	10
346	Oral Cancer: Genetics and the Role of Precision Medicine. 2020 , 29, 127-144	13
345	Enhancing the efficacy of immunotherapy using radiotherapy. 2020 , 9, e1169	16
344	Cancer stem cells and strategies for targeted drug delivery. 2021 , 11, 1779-1805	3
343	Visualizing Human Colorectal Cancer Intratumor Heterogeneity with Phylogeography. 2020 , 23, 101304	3
342	Genomics-based immuno-oncology: bridging the gap between immunology and tumor biology. 2020 , 29, R214-R225	1
341	Emerging role of tumor cell plasticity in modifying therapeutic response. 2020 , 5, 228	35
340	Cancer cells undergoing epigenetic transition show short-term resistance and are transformed into cells with medium-term resistance by drug treatment. 2020 , 52, 1102-1115	5
339	Single-cell lineage analysis reveals genetic and epigenetic interplay in glioblastoma drug resistance. 2020 , 21, 174	23
338	Epithelial-mesenchymal transition in cancer. 2020 , 553-568	1
337	Methylation of the Promoter Region of the Tight Junction Protein-1 by DNMT1 Induces EMT-like Features in Multiple Myeloma. 2020 , 19, 197-207	0
336	Genetic and epigenetic determinants of diffuse large B-cell lymphoma. 2020 , 10, 123	22
335	Capturing complex epigenetic phenomena through human multicellular systems. 2020 , 16, 34-41	0
334	Tonicity-responsive enhancer-binding protein promotes stemness of liver cancer and cisplatin resistance. 2020 , 58, 102926	6

333	Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors. 2020 , 10,	22
332	Stress Granules in Cancer. 2020 , 1	8
331	Glioma stem-like cells evade interferon suppression through MBD3/NuRD complex-mediated STAT1 downregulation. 2020 , 217,	14
330	Next-generation DNA damage sequencing. 2020 , 49, 7354-7377	21
329	Extracellular Vesicle-Based Communication May Contribute to the Co-Evolution of Cancer Stem Cells and Cancer-Associated Fibroblasts in Anti-Cancer Therapy. 2020 , 12,	4
328	Impact of the Tumor Microenvironment on Tumor Heterogeneity and Consequences for Cancer Cell Plasticity and Stemness. 2020 , 12,	31
327	Cell-Free DNA-Methylation-Based Methods and Applications in Oncology. 2020 , 10,	13
326	The Intimate Relationship Among EMT, MET and TME: A T(ransdifferentiation) E(nhancing) M(ix) to Be Exploited for Therapeutic Purposes. 2020 , 12,	16
325	LncRNA LHFPL3-AS1 contributes to tumorigenesis of melanoma stem cells via the miR-181a-5p/BCL2 pathway. 2020 , 11, 950	15
324	Advances in Histone Demethylase KDM3A as a Cancer Therapeutic Target. 2020 , 12,	14
323	Cancer Stem Cell Plasticity - A Deadly Deal. 2020 , 7, 79	33
322	Recent Advances in Cancer Plasticity: Cellular Mechanisms, Surveillance Strategies, and Therapeutic Optimization. 2020 , 10, 569	13
321	Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer. 2020 , 69, 1989-1999	29
320	Epigenetics in Inflammatory Breast Cancer: Biological Features and Therapeutic Perspectives. 2020 , 9,	6
319	Role of Mitochondria in Generation of Phenotypic Heterogeneity in Yeast. 2020 , 100, 497-514	
318	Resolving DNA Damage: Epigenetic Regulation of DNA Repair. 2020 , 25,	17
317	Identification of genes associated with cancer stem cell characteristics in head and neck squamous cell carcinoma through co-expression network analysis. 2020 , 42, 2460-2472	1
316	The Number of Transcription Factors at an Enhancer Determines Switch-like Gene Expression. 2020 , 31, 107724	13

315	AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy. 2020 , 87, 13-19	4
314	Broadening Drug Design and Targets to Tumor Microenvironment? Cancer-Associated Fibroblast Marker Expression in Cancers and Relevance for Survival Outcomes. 2020 , 24, 340-351	13
313	Prevention of tumor risk associated with the reprogramming of human pluripotent stem cells. 2020 , 39, 100	21
312	Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression. 2020 , 11, 1469	21
311	PIK3C3 regulates the expansion of liver CSCs and PIK3C3 inhibition counteracts liver cancer stem cell activity induced by PI3K inhibitor. 2020 , 11, 427	12
310	Minimal barriers to invasion during human colorectal tumor growth. 2020 , 11, 1280	12
309	Dynamic Signatures of the Epigenome: Friend or Foe?. 2020 , 9,	8
308	Targeting cancer stem cells by melatonin: Effective therapy for cancer treatment. 2020 , 216, 152919	19
307	Targeting Epigenetic Dependencies in Solid Tumors: Evolutionary Landscape Beyond Germ Layers Origin. 2020 , 12,	4
306	Springing an evolutionary trap on cancer. 2020 , 52, 361-362	1
305	Long non-coding RNAs regulate drug resistance in cancer. 2020 , 19, 54	62
304	A Modified Lentivirus-Based Reporter for Magnetic Separation of Cancer Stem Cells. 2020 , 54, 82-88	1
303	CDK5RAP3 as tumour suppressor negatively regulates self-renewal and invasion and is regulated by ERK1/2 signalling in human gastric cancer. 2020 , 123, 1131-1144	5
302	Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer. 2020 , 12, 2896-2909	2
301	Radiation-induced bystander and abscopal effects: important lessons from preclinical models. 2020 , 123, 339-348	25
300	Phenotypic plasticity: the emergence of cancer stem cells and collective cell migration. 2020 , 639-649	0
299	Evaluation of the tumor-targeting efficiency and intratumor heterogeneity of anticancer drugs using quantitative mass spectrometry imaging. 2020 , 10, 2621-2630	14
298	5-(Carbamoylmethylene)-oxazolidin-2-ones as a Promising Class of Heterocycles Inducing Apoptosis Triggered by Increased ROS Levels and Mitochondrial Dysfunction in Breast and Cervical Cancer. 2020 , 8,	10

297	Tumor-Oriented Telomerase-Terminated Nanoplatform as Versatile Strategy for Multidrug Resistance Reversal in Cancer Treatment. 2020 , 9, e1901739	6
296	Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification. 2020 , 14, 671-685	11
295	Understanding the role of phenotypic switching in cancer drug resistance. 2020 , 490, 110162	14
294	Directly targeting glutathione peroxidase 4 may be more effective than disrupting glutathione on ferroptosis-based cancer therapy. 2020 , 1864, 129539	15
293	Epigenetic plasticity potentiates a rapid cyclical shift to and from an aggressive cancer phenotype. 2020 , 146, 3065-3076	6
292	Alternative polyadenylation drives oncogenic gene expression in pancreatic ductal adenocarcinoma. 2020 , 30, 347-360	22
291	The combination of disulfiram and copper for cancer treatment. 2020 , 25, 1099-1108	34
290	Cell plasticity in cancer: A complex interplay of genetic, epigenetic mechanisms and tumor micro-environment. 2020 , 34, 154-162	8
289	Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy. 2020 , 19, 79	82
288	Super-Enhancer Redistribution as a Mechanism of Broad Gene Dysregulation in Repeatedly Drug-Treated Cancer Cells. 2020 , 31, 107532	16
287	Aquaporin-9, Mediated by IGF2, Suppresses Liver Cancer Stem Cell Properties via Augmenting ROS/ECatenin/FOXO3a Signaling. 2020 , 18, 992-1003	13
286	Targeting NAD Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance. 2020 , 18, 1004-1017	7
285	Salinomycin inhibits epigenetic modulator EZH2 to enhance death receptors in colon cancer stem cells. 2021 , 16, 144-161	10
284	The bitter side of epigenetics: variability and resistance to chemotherapy. 2021 , 13, 397-403	2
283	Effect of feedback regulation on stem cell fractions in tissues and tumors: Understanding chemoresistance in cancer. 2021 , 509, 110499	2
282	Cancer Stem Cell Markers in Relation to Patient Survival Outcomes: Lessons for Integrative Diagnostics and Next-Generation Anticancer Drug Development. 2021 , 25, 81-92	7
281	Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. 2021 , 2, 54-69	6
280	Mathematical Models of Cancer and Different Therapies. 2021 ,	3

279	Targeting Epigenetics in Lung Cancer. 2021 , 11,	4
278	Efficacy of Novel Bromodomain and Extraterminal Inhibitors in Combination with Chemotherapy for Castration-Resistant Prostate Cancer. 2021 , 4, 437-446	6
277	refMiR 142 5p inhibits cell invasion and migration by targeting DNMT1 in breast cancer. 2021 ,	0
276	Low-dose HDACi potentiates anti-tumor activity of macrophages in immunotherapy. 2021 , 10, 1935668	1
275	Intratumor heterogeneity of breast cancer detected by epialleles shows association with hypoxic microenvironment. 2021 , 11, 4403-4420	2
274	PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. 2021 , 11, 5387-5403	3
273	DNA methylation inhibitors: Retrospective and perspective view. 2021 , 152, 205-223	2
272	Spatial Epitope Barcoding Reveals Subclonal Tumor Patch Behaviors.	0
271	Systematic screening reveals synergistic interactions that overcome MAPK inhibitor resistance in cancer cells. 2021 ,	
270	Drug Resistance in Cancer. 2021 , 367-386	0
269	Epigenetic targeting of cancer stem cells by polyphenols (cancer stem cells targeting). 2021 , 35, 3649-3664	4
268	The BET Inhibitor OTX015 Exhibits In Vitro and In Vivo Antitumor Activity in Pediatric Ependymoma Stem Cell Models. 2021 , 22,	3
267	Biophysical Informatics Approach For Quantifying Phenotypic Heterogeneity In Cancer Cell Migration In Confined Microenvironments. 2021 ,	5
266	Cancer stem cells and macrophages: molecular connections and future perspectives against cancer. 2021 , 12, 230-250	7
265	Epigenetic Control of Infant B Cell Precursor Acute Lymphoblastic Leukemia. 2021 , 22,	0
264	Aberrant expression of thyroid transcription factor-1 in meningeal solitary fibrous tumor/hemangiopericytoma. 2021 , 38, 122-131	
263	CENP-A overexpression promotes distinct fates in human cells, depending on p53 status. 2021 , 4, 417	11
262	The potential of long noncoding RNAs for precision medicine in human cancer. 2021 , 501, 12-19	10

261	Current paradigms in epigenetic anticancer therapeutics and future challenges. 2021,	8
260	BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair. 2021, 40, 2711-2724	5
259	Morphodynamic signatures of MDA-MB-231 single cells and cell doublets undergoing invasion in confined microenvironments. 2021, 11, 6529	4
258	Dynamic plasticity within the EMT spectrum, rather than static mesenchymal traits, drives tumor heterogeneity and metastatic progression of breast cancers.	4
257	Defining proximity proteomics of post-translationally modified proteins by antibody-mediated protein A-APEX2 labeling.	
256	Integrative RNA-Seq and H3 Trimethylation ChIP-Seq Analysis of Human Lung Cancer Cells Isolated by Laser-Microdissection. 2021, 13,	0
255	Sec62 promotes stemness and chemoresistance of human colorectal cancer through activating Wnt/ β -catenin pathway. 2021, 40, 132	26
254	Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5Pdeoxy-5-fluorocytidine (5PDFCR). 2021, 40, 138	1
253	Role of Chromodomain-Helicase-DNA-Binding Protein 4 (CHD4) in Breast Cancer. 2021, 11, 633233	1
252	Role of Epigenetic Regulation in Plasticity of Tumor Immune Microenvironment. 2021, 12, 640369	12
251	Autophagy signals orchestrate chemoresistance of gynecological cancers. 2021, 1875, 188525	3
250	Cancer Stem Cells Are Possible Key Players in Regulating Anti-Tumor Immune Responses: The Role of Immunomodulating Molecules and MicroRNAs. 2021, 13,	3
249	Farnesoid X receptor via Notch1 directs asymmetric cell division of Sox9 cells to prevent the development of liver cancer in a mouse model. 2021, 12, 232	4
248	Reck-Notch1 Signaling Mediates miR-221/222 Regulation of Lung Cancer Stem Cells in NSCLC. 2021, 9, 663279	1
247	PET Molecular Imaging: A Holistic Review of Current Practice and Emerging Perspectives for Diagnosis, Therapeutic Evaluation and Prognosis in Clinical Oncology. 2021, 22,	13
246	MicroRNA Expression Profile Distinguishes Glioblastoma Stem Cells from Differentiated Tumor Cells. 2021, 11,	4
245	Metabolites in the Tumor Microenvironment Reprogram Functions of Immune Effector Cells Through Epigenetic Modifications. 2021, 12, 641883	1
244	Selective Anti-Cancer Effects of Plasma-Activated Medium and Its High Efficacy with Cisplatin on Hepatocellular Carcinoma with Cancer Stem Cell Characteristics. 2021, 22,	7

243	Metameric representations on optimization of nano particle cancer treatment. 2021 , 41, 352-361	3
242	The language of chromatin modification in human cancers. 2021 , 21, 413-430	35
241	Stochastic fluctuations drive non-genetic evolution of proliferation in clonal cancer cell populations.	0
240	Mechanisms of cancer stem cell senescence: Current understanding and future perspectives. 2021 , 48, 1185-1202	3
239	Starvation and Climate Change How to Constrain Cancer Cell Epigenetic Diversity and Adaptability to Enhance Treatment Efficacy. 2021 , 9,	0
238	Fascin promotes the invasion of pituitary adenoma through partial dependence on epithelial-mesenchymal transition. 2021 , 52, 823-838	
237	Probing low-copy-number proteins in single living cells using single-cell plasmonic immunosandwich assays. 2021 , 16, 3522-3546	7
236	Spatial epitope barcoding reveals subclonal tumor patch behaviors.	0
235	The epigenetics of breast cancer - Opportunities for diagnostics, risk stratification and therapy. 2021 , 1-13	7
234	Cellular senescence or stemness: hypoxia flips the coin. 2021 , 40, 243	3
233	Lineage Plasticity in Cancer: The Tale of a Skin-Walker. 2021 , 13,	2
232	Epigenetic modulators for brain cancer stem cells: Implications for anticancer treatment. 2021 , 13, 670-684	3
231	Inflammation and tumor progression: signaling pathways and targeted intervention. 2021 , 6, 263	107
230	Genome-wide DNA methylome analysis identifies methylation signatures associated with survival and drug resistance of ovarian cancers. 2021 , 13, 142	2
229	HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity. 2021 , 13,	7
228	Disentangling tumorigenesis-associated DNA methylation changes in colorectal tissues from those associated with ageing. 2021 , 1-18	
227	Optical Cellular Micromotion: A New Paradigm to Measure Tumour Cells Invasion in 3D Tumour Environments.	
226	Translocation of intracellular CD24 constitutes a triggering event for drug resistance in breast cancer. 2021 , 11, 17077	0

225	Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer. 2021 , 131,	1
224	Epigenetic signatures differentiate uterine and soft tissue leiomyosarcoma. 2021 , 12, 1566-1579	3
223	Resistance to platinum-based cancer drugs: a special focus on epigenetic mechanisms. 2021 , 22, 777-790	0
222	Predator-Prey in Tumor-Immune Interactions: A Wrong Model or Just an Incomplete One?. 2021 , 12, 668221	3
221	A 14-Marker Multiplexed Imaging Panel for Prognostic Biomarkers and Tumor Heterogeneity in Head and Neck Squamous Cell Carcinoma. 2021 , 11, 713561	1
220	Insight of nanomedicine strategies for a targeted delivery of nanotherapeutic cues to cope with the resistant types of cancer stem cells. 2021 , 64, 102681	5
219	KMT2D Loss Promotes Head and Neck Squamous Carcinoma Through Enhancer Reprogramming and Modulation of Immune Microenvironment.	0
218	Single-cell multimodal glioma analyses identify epigenetic regulators of cellular plasticity and environmental stress response. 2021 , 53, 1456-1468	9
217	Analysis of whole-exome data of cfDNA and the tumor tissue of non-small cell lung cancer. 2021 , 9, 1453	
216	Extracellular Matrix Characterization in Gastric Cancer Helps to Predict Prognosis and Chemotherapy Response. 2021 , 11, 753330	0
215	Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor. 2021 , 39, 1404-1421.e11	6
214	Small extrachromosomal circular DNA (eccDNA): major functions in evolution and cancer. 2021 , 20, 113	6
213	A Novel Therapeutic Strategy Targeting the Mesenchymal Phenotype of Malignant Pleural Mesothelioma By Suppressing LSD1. 2021 ,	2
212	Defining Proximity Proteomics of Histone Modifications by Antibody-mediated Protein A-APEX2 Labeling. 2021 ,	0
211	Global analysis of a cancer model with drug resistance due to Lamarckian induction and microvesicle transfer. 2021 , 527, 110812	
210	Peptide-drug conjugate-based novel molecular drug delivery system in cancer. 2021 , 42, 857-869	6
209	The Mutation and Expression Level of LRP1B are Associated with Immune Infiltration and Prognosis in Hepatocellular Carcinoma. 2021 , 14, 6343-6358	1
208	Unlocking the Signal Transduction between Glioma-initiating Cells of Tumor Edge. 2021 ,	

207	Quantitative Analysis of Circulating Tumor Cells Using RNA-Based Digital Scoring. 2020 , 215, 77-88	1
206	Epigenetic Control Using Small Molecules in Cancer. 2020 , 111-148	1
205	Therapeutic Cancer Vaccines. 2016 , 909, 139-67	11
204	The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review. 2020 , 37, 3059-3082	27
203	Epigenetic regulation of cancer stem cell and tumorigenesis. 2020 , 148, 1-26	7
202	Causes, effects, and clinical implications of perturbed patterns within the cancer epigenome. 2020 ,	6
201	Epigenetic plasticity, selection, and tumorigenesis. 2020 , 48, 1609-1621	4
200	G9a methyltransferase governs cell identity in the lung and is required for KRAS G12D tumor development and propagation.	0
199	CENP-A overexpression drives distinct cell fates depending on p53 status.	1
198	Single-cell multimodal glioma analyses reveal epigenetic regulators of cellular plasticity and environmental stress response.	2
197	Bivalent chromatin protects reversibly repressed genes from irreversible silencing.	5
196	Joint single-cell DNA accessibility and protein epitope profiling reveals environmental regulation of epigenomic heterogeneity.	3
195	Linking single-cell measurements of mass, growth rate, and gene expression.	1
194	Kinetic Inference Resolves Epigenetic Mechanism of Drug Resistance in Melanoma.	4
193	Aberrant methylation of PCDH8 is a potential prognostic biomarker for patients with clear cell renal cell carcinoma. 2014 , 20, 2380-5	16
192	Doxorubicin-provoked increase of mitotic activity and concomitant drain of G0-pool in therapy-resistant BE(2)-C neuroblastoma. 2018 , 13, e0190970	5
191	Epigenetic Biomarkers in Head and Neck Cancer. 2017 , 1, 41-50	3
190	90 YEARS OF PROGESTERONE: Steroid receptors as MAPK signaling sensors in breast cancer: let the fates decide. 2020 , 65, T35-T48	8

189	Twenty Years on: What Do We Really Know about Ewing Sarcoma and What Is the Path Forward?. 2015 , 20, 155-71	68
188	Mitochondrial fission and stemness in prostate cancer. 2019 , 11, 8036-8038	4
187	RNAi screens identify CHD4 as an essential gene in breast cancer growth. 2016 , 7, 80901-80915	24
186	Hypoxia-inducible factor-2 alpha up-regulates CD70 under hypoxia and enhances anchorage-independent growth and aggressiveness in cancer cells. 2018 , 9, 19123-19135	12
185	The landscape of novel and complementary targets for immunotherapy: an analysis of gene expression in the tumor microenvironment. 2019 , 10, 4532-4545	6
184	Targeting tumor-initiating cells: eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction. 2015 , 6, 4585-601	46
183	Hormone stimulation of androgen receptor mediates dynamic changes in DNA methylation patterns at regulatory elements. 2015 , 6, 42575-89	26
182	Analogues of the novel phytohormone, strigolactone, trigger apoptosis and synergize with PARP inhibitors by inducing DNA damage and inhibiting DNA repair. 2016 , 7, 13984-4001	26
181	Transcriptome-wide analysis of compression-induced microRNA expression alteration in breast cancer for mining therapeutic targets. 2016 , 7, 27468-78	19
180	LGR5 expression is controlled by IKK β in basal cell carcinoma through activating STAT3 signaling pathway. 2016 , 7, 27280-94	20
179	A new view of the mammary epithelial hierarchy and its implications for breast cancer initiation and metastasis. 2019 , 5,	3
178	Drug resistance and combating drug resistance in cancer. 2019 , 2, 141-160	138
177	The role of exosomal long non-coding RNAs in cancer drug resistance. 2019 , 2, 1178-1192	17
176	Functional Polymorphism in the Gene Promoter Confers a Decreased Risk of Lung Cancer in Chinese by Reducing Expression. 2018 , 19, 375-383	3
175	Peptides as Potential Anticancer Agents. 2019 , 19, 1491-1511	13
174	Pharmacoeugenetics and Pharmacoeugenomics: An Overview. 2019 , 16, 392-399	5
173	Intratumoral spatial heterogeneity of BTK kinomic activity dictates distinct therapeutic response within a single glioblastoma tumor. 2019 , 1-12	4
172	Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity. 2020 , 21,	159

171	Epigenetic activation of FOXF1 confers cancer stem cell properties to cisplatin-resistant non-small cell lung cancer. 2020 , 56, 1083-1092	2
170	Metabolic Signaling to Epigenetic Alterations in Cancer. 2018 , 26, 69-80	20
169	Marine-derived Fungi Extracts Enhance the Cytotoxic Activity of Doxorubicin in Nonsmall Cell Lung Cancer Cells A459. 2017 , 9, S92-S98	11
168	Far Beyond Cancer Immunotherapy: Reversion of Multi-Malignant Phenotypes of Immunotherapeutic-Resistant Cancer by Targeting the NANOG Signaling Axis. 2020 , 20, e7	6
167	Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine. 2015 , 5, 23-42	153
166	Flura-seq identifies organ-specific metabolic adaptations during early metastatic colonization. 2019 , 8,	26
165	Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance. 2019 , 8,	33
164	Determination of the Subclonal Tumor Structure in Childhood Acute Myeloid Leukemia and Acral Melanoma by Next-Generation Sequencing. 2021 , 55, 727-741	
163	Epigenetic Signaling of Cancer Stem Cells During Inflammation. 2021 , 9, 772211	4
162	Lineage Recording Reveals the Phylodynamics, Plasticity and Paths of Tumor Evolution.	0
161	Decoding the function of bivalent chromatin in development and cancer. 2021 ,	3
160	Chi3l1 is a modulator of glioma stem cell states and a therapeutic vulnerability for glioblastoma.	1
159	Insight into Cancer Stem Cell Niche; Lessons from Cancer Stem Cell Models Generated In Vitro. 2015 , 211-226	
158	Editorial - From robot to molecule, the behavior. 2016 , 42, 409-12	
157	Homeostasis Back and Forth: An Eco-Evolutionary Perspective of Cancer.	2
156	Lung Cancer Stem Cells. 2018 , 45-56	
155	Targeting temporal dynamics of microenvironmental factors halts tumor migration and alleviates effects of dynamic tumor heterogeneity.	
154	Stem Cell-Associated Heterogeneity in Glioblastoma Is a Result of Intrinsic Tumor Plasticity Shaped by the Microenvironment.	

- 153 Inhibition of mitochondrial ferredoxin 1 (FDX1) prevents adaptation to proteotoxic stress.
- 152 Multi-scale modeling reveals angiogenesis-induced drug resistance in brain tumor and predicts a synergistic drug combination targeting EGFR and VEGFR pathways.
- 151 Cell-Type Switches Induced by Stochastic Histone Modification Inheritance.
- 150 5-Methylcytosine and Its Oxidized Derivatives. **2019**, 65-86
- 149 Targeting Epigenetic Regulators in Cancer to Overcome Targeted Therapy Resistance. **2019**, 217-232
- 148 The invasion of de-differentiating cancer cells into hierarchical tissues.
- 147 Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance.
- 146 Branched-Chain Amino Acid Metabolic Reprogramming Orchestrates Drug Resistance to EGFR Tyrosine Kinase Inhibitors.
- 145 Study of association between molecular marker expression on tumor and immunocompetent cells and sensitivity to adjuvant and neoadjuvant therapy of bladder cancer. **2019**, 15, 100-106 1
- 144 Alternative polyadenylation drives oncogenic gene expression in pancreatic ductal adenocarcinoma. 0
- 143 Minimal Barriers to Invasion During Human Colorectal Tumor Growth.
- 142 Intracellular Energy Variability Modulates Cellular Decision-Making Capacity.
- 141 Salinomycin inhibits epigenetic modulator EZH2 to enhance Death Receptors in Colon Cancer Stem Cells. 2
- 140 Aberrant epigenetic silencing of neuronatin is a frequent event in human osteosarcoma. **2020**, 11, 1876-1893 2
- 139 Global analysis of a cancer model with drug resistance due to Lamarckian induction and microvesicle transfer. 0
- 138 EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma. **2021**, 11, 21396 4
- 137 Metabolic Changes and Their Characterization. **2020**, 35-70
- 136 Natural molecules as modulators of epigenetic silencing in human cells for cancer care and aging. **2020**, 65,

- 135 Chromatin plasticity in pluripotent and cancer stem cells. **2020**, 207-230
- 134 Cancer Stem Cells and the Development of Cancer. **2020**, 151-192
- 133 Cancer stem cells, plasticity, and drug resistance.. **2020**, 3, 140-148
- 132 Exaptation for the Good and the Bad: Regeneration and Cancer. **2020**, 47-53 0
- 131 Time Series Data to Mathematical Model. **2021**, 15-54
- 130 Predicting heterogeneity in clone-specific therapeutic vulnerabilities using single-cell transcriptomic signatures. 0
- 129 Cancer Epigenomics and Beyond: Advancing the Precision Oncology Paradigm. **2020**, 3, 147-156
- 128 Elevated expression of MDR1 associated with Line-1 hypomethylation in esophageal squamous cell carcinoma. **2015**, 8, 14392-400 8
- 127 Stress-triggered atavistic reprogramming (STAR) addiction: driving force behind head and neck cancer?. **2016**, 6, 1149-66 7
- 126 HLA-E inhibitor enhances the killing of neuroblastoma stem cells by co-cultured dendritic cells and cytokine-induced killer cells loaded with membrane-based microparticles. **2017**, 7, 334-345
- 125 [Reconstruction of tumor clonal haplotypes based on an improved spanning algorithm]. **2019**, 39, 1287-1292
- 124 [Research Advances of m⁶A RNA Methylation in Non-small Cell Lung Cancer]. **2020**, 23, 961-969 0
- 123 Immunotherapeutic strategies for sarcoma: current perspectives. **2020**, 12, 7693-7701 1
- 122 Mitochondrial Plasticity Promotes Resistance to Sorafenib and Vulnerability to STAT3 Inhibition in Human Hepatocellular Carcinoma. **2021**, 13, 0
- 121 Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer. **2021**, 1 0
- 120 Hypo-trimethylation of Histone H3 Lysine 4 and Hyper-tri/dimethylation of Histone H3 Lysine 27 as Epigenetic Markers of Poor Prognosis in Patients with Primary Central Nervous System Lymphoma. **2021**, 1
- 119 Mathematical characterization of population dynamics in breast cancer cells treated with doxorubicin.
- 118 LncRNAs, the Molecules Involved in Communications With Colorectal Cancer Stem Cells.. **2022**, 12, 811374 0

117	Epigenetic Drugs and Their Immune Modulating Potential in Cancers.. 2022 , 10,	
116	Melatonin: Regulation of Prion Protein Phase Separation in Cancer Multidrug Resistance.. 2022 , 27,	3
115	Mitochondrial DNA copy number as a prognostic marker is age-dependent in adult glioblastoma.. 2022 , 4, vdab191	0
114	Development and application of novel BiFC probes for cell sorting based on epigenetic modification.. 2022 ,	0
113	Advanced techniques for gene heterogeneity research: Single-cell sequencing and on-chip gene analysis systems. 2022 , 3, 20210011	
112	EHMT1/EHMT2 in EMT, Cancer Stemness and Drug Resistance: Emerging Evidence and Mechanisms.. 2021 ,	2
111	Emerging roles of epithelial-mesenchymal plasticity in invasion-metastasis cascade and therapy resistance.. 2022 , 41, 131	2
110	Cancer and regulation of gene expression. 2022 , 205-216	
109	Crosstalk between non-coding RNAs expression profile, drug resistance and immune response in breast cancer.. 2021 , 106041	0
108	Sox2 induces glioblastoma cell stemness and tumor propagation by repressing TET2 and deregulating 5hmC and 5mC DNA modifications.. 2022 , 7, 37	1
107	Mechanisms of Cisplatin Resistance in HPV Negative Head and Neck Squamous Cell Carcinomas.. 2022 , 11,	1
106	Plasticity within aldehyde dehydrogenase-positive cells determines prostate cancer radiosensitivity.. 2022 ,	1
105	Anticancer drug resistance: An update and perspective.. 2021 , 100796	17
104	Pre-treatment hematological parameters as a cost effective predictive marker for response to concurrent chemo radiation in locally advanced cervical cancer.. 2022 , 31, 100539	0
103	Aberrant DNA methylation impacts HOX genes expression in bone marrow mesenchymal stromal cells of myelodysplastic syndromes and de novo acute myeloid leukemia.. 2022 ,	0
102	Epigenetic Regulation: A Link between Inflammation and Carcinogenesis.. 2022 , 14,	1
101	Cellular plasticity upon proton irradiation determines tumor cell radiosensitivity.. 2022 , 38, 110422	2
100	Homologous targeting nanoparticles for enhanced PDT against osteosarcoma HOS cells and the related molecular mechanisms.. 2022 , 20, 83	2

99	HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation.. 2022 , 41, 83	1
98	Targeting key proteins involved in transcriptional regulation for cancer therapy: Current strategies and future prospective.. 2022 ,	3
97	The identification of the anthracycline aclarubicin as an effective cytotoxic agent for pancreatic cancer.. 2022 ,	2
96	The crucial roles of m6A RNA modifications in cutaneous cancers: Implications in pathogenesis, metastasis, drug resistance, and targeted therapies. 2022 ,	
95	Transition Therapy: Tackling the Ecology of Tumor Phenotypic Plasticity.. 2021 , 84, 24	0
94	Quantification of tumor heterogeneity: from data acquisition to metric generation.. 2021 ,	0
93	Reciprocal regulation of BRN2 and NOTCH1/2 signaling synergistically drives melanoma cell migration and invasion.. 2021 ,	
92	Predicting heterogeneity in clone-specific therapeutic vulnerabilities using single-cell transcriptomic signatures.. 2021 , 13, 189	5
91	Single-cell transcriptome atlas of human mesenchymal stem cells exploring cellular heterogeneity.. 2021 , 11, e650	5
90	Cell-of-Origin and Genetic, Epigenetic, and Microenvironmental Factors Contribute to the Intra-Tumoral Heterogeneity of Pediatric Intracranial Ependymoma. 2021 , 13,	1
89	The Role of Janus Kinase/STAT3 Pathway in Hematologic Malignancies With an Emphasis on Epigenetics.. 2021 , 12, 703883	1
88	Recurrence of cancer cell states across diverse tumors and their interactions with the microenvironment.	0
87	Understanding Drug Sensitivity and Tackling Resistance in Cancer.. 2022 ,	1
86	The Potential Role of Mitochondrial Acetaldehyde Dehydrogenase 2 in Urological Cancers From the Perspective of Ferroptosis and Cellular Senescence.. 2022 , 10, 850145	0
85	Identification of Tumor Microenvironment and DNA Methylation-Related Prognostic Signature for Predicting Clinical Outcomes and Therapeutic Responses in Cervical Cancer.. 2022 , 9, 872932	1
84	The paradigm of drug resistance in cancer: an epigenetic perspective.. 2022 , 42,	2
83	DataSheet_1.doc. 2019 ,	
82	Presentation_1.ppt. 2019 ,	

81	Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution.. 2022,	4
80	Docosahexaenoic acid may promote immune evasion of colorectal cancer cells through targeting immune checkpoint and immunomodulator genes and their controlling microRNAs.. 2022,	
79	Engineered colorectal cancer tissue recapitulates key attributes of a patient-derived xenograft tumor line.	0
78	On tumoural growth and treatment under cellular dedifferentiation.	
77	Epi-immunotherapy for cancers: rationales of epi-drugs in combination with immunotherapy and advances in clinical trials.	2
76	The Role of AXL Receptor Tyrosine Kinase in Cancer Cell Plasticity and Therapy Resistance. 2022, 307-327	
75	Optical Cellular Micromotion: A New Paradigm to Measure Tumor Cells Invasion within Gels Mimicking the 3D Tumor Environments. 2200471	1
74	Scales of Cancer Evolution: Selfish Genome or Cooperating Cells?. 2022, 14, 3253	0
73	Epialleles and epiallelic heterogeneity in hematological malignancies. 2022, 39,	0
72	The Origin and Evolution of Bladder Cancer Stem Cells. 10,	
71	Radiotherapy combined with immunotherapy: the dawn of cancer treatment. 2022, 7,	8
70	Cancer cell states recur across tumor types and form specific interactions with the tumor microenvironment. 2022, 54, 1192-1201	1
69	Investigating and modeling the differential DNA methylation for early lung adenocarcinoma diagnosis.	
68	An Epigenetic Role of Mitochondria in Cancer. 2022, 11, 2518	5
67	EHMT2 methyltransferase governs cell identity in the lung and is required for KRASG12D tumor development and propagation. 11,	
66	Disruption of cancer cell functions by task-specific drug perturbations. 13,	
65	DNA Methyltransferase 3B Mediated Intratumoral Heterogeneity and Therapeutic Targeting in Breast Cancer Recurrence and Metastasis. OF1-OF12	
64	Targeting histone methylation to reprogram the transcriptional state that drives survival of drug-tolerant myeloid leukemia persists. 2022, 105013	1

63	Phenotypic heterogeneity driven by plasticity of the intermediate EMT state governs disease progression and metastasis in breast cancer. 2022 , 8,	5
62	Cancer stem cell plasticity and its implications in the development of new clinical approaches for oral squamous cell carcinoma. 2022 , 204, 115212	0
61	CD44-targeted nanoparticles with GSH-responsive activity as powerful therapeutic agents against breast cancer. 2022 , 221, 1491-1503	0
60	Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert. 2022 , 86, 14-27	2
59	Cellular reprogramming, chemoresistance, and dietary interventions in breast cancer. 2022 , 179, 103796	0
58	Cancer Epigenetics. 2023 , 697-714	0
57	Polypharmacology in Drug Design and Discovery Basis for Rational Design of Multitarget Drugs. 2022 , 397-533	0
56	Quantifying epithelial-mesenchymal heterogeneity and EMT scoring in tumor samples via tyramide signal amplification (TSA). 2022 , 149-161	0
55	Cisplatin Resistance: Genetic and Epigenetic Factors Involved. 2022 , 12, 1365	0
54	Mathematical characterization of population dynamics in breast cancer cells treated with doxorubicin. 9,	0
53	TNFAIP3 promotes ALDH-positive breast cancer stem cells through FGFR1/MEK/ERK pathway. 2022 , 39,	0
52	DNA methylation-mediated low expression of ZNF582 promotes the proliferation, migration, and invasion of clear cell renal cell carcinoma.	0
51	Predicting Anti-Cancer Drug Combination Responses with a Temporal Cell State Network Model.	0
50	Reprogramming Carbohydrate Metabolism in Cancer and Its Role in Regulating the Tumor Microenvironment. 2022 , 3-65	0
49	Evolutionary analysis of replicator dynamics about anti-cancer combination therapy. 2022 , 20, 656-682	0
48	Chromosomal Instability, Selection and Competition: Factors That Shape the Level of Karyotype Intra-Tumor Heterogeneity. 2022 , 14, 4986	1
47	Long-Term Fenofibrate Treatment Stimulates the Phenotypic Microevolution of Prostate Cancer Cells In Vitro. 2022 , 15, 1320	0
46	Targeting cancer stem cells and signalling pathways through phytochemicals: A promising approach against colorectal cancer. 2022 , 154524	0

45	Long non-coding RNA HOTAIR regulates the stemness of breast cancer cells via activation of the NF- κ B signaling pathway. 2022 , 102630	0
44	Epigenetic regulation of RARB overcomes the radio-resistance of colorectal carcinoma cells via cancer stem cells.	0
43	Chemical Carcinogenesis. 1-23	0
42	Induction of promyelocytic leukemia zinc finger protein by miR-200c-3p restores sensitivity to anti-androgen therapy in androgen-refractory prostate cancer and inhibits the cancer progression via down-regulation of integrin β 4.	1
41	Spatial epitope barcoding reveals clonal tumor patch behaviors. 2022 ,	0
40	Three-Dimensional in Vitro Models: A Promising Tool To Scale-Up Breast Cancer Research.	1
39	Biological Hallmarks of Cancer. 1-10	0
38	HES1 promoter activation dynamics reveal the plasticity, stemness and heterogeneity in neuroblastoma cancer stem cells.	0
37	On tumoural growth and treatment under cellular dedifferentiation. 2023 , 557, 111327	0
36	Epigenetic regulation of bone remodeling and bone metastasis. 2022 ,	0
35	Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress. 2022 , 27,	0
34	Generation and Evaluation of Hydrogel-Facilitated 3D Tumor Microenvironments of Breast Cancer. 2022 , 12,	0
33	Modern view on the treatment of oncological diseases by endovascular methods. 2022 , 9, 33-40	0
32	The importance of fusion protein activity in Ewing sarcoma and the cell intrinsic and extrinsic factors that regulate it: A review. 12,	1
31	Down-Regulation of lncRNA MBNL1-AS1 Promotes Tumor Stem Cell-like Characteristics and Prostate Cancer Progression through miR-221-3p/CDKN1B/C-myc Axis. 2022 , 14, 5783	0
30	Breast cancer plasticity is restricted by a LATS1-NCOR1 repressive axis. 2022 , 13,	0
29	An Epigenetic LINE-1-Based Mechanism in Cancer. 2022 , 23, 14610	0
28	Elevated methionine flux drives pyroptosis evasion in persister cancer cells.	0

- 27 Phytochemicals as Chemo-Preventive Agents and Signaling Molecule Modulators: Current Role in Cancer Therapeutics and Inflammation. **2022**, 23, 15765 ○
- 26 Integration of Quantitative Methods and Mathematical Approaches for the Modeling of Cancer Cell Proliferation Dynamics. ○
- 25 Stochastic Fluctuations Drive Non-genetic Evolution of Proliferation in Clonal Cancer Cell Populations. **2023**, 85, ○
- 24 Application of individualized multimodal radiotherapy combined with immunotherapy in metastatic tumors. 13, ○
- 23 Cancer plasticity: Investigating the causes for this agility. **2023**, 88, 138-156 ○
- 22 Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition. 13, ○
- 21 DNA methylation and cancer: transcriptional regulation, prognostic, and therapeutic perspective. **2023**, 40, ○
- 20 Bromodomain (BrD) Family Members as Regulators of Cancer Stemness: A Comprehensive Review. **2023**, 24, 995 ○
- 19 Development of Human Adrenocortical Adenoma (HAA1) Cell Line from Zona Reticularis. **2023**, 24, 584 ○
- 18 Long Non-Coding RNAs as Epigenetic Regulators of Immune Checkpoints in Cancer Immunity. **2023**, 15, 184 ○
- 17 Biophysical informatics reveals distinctive phenotypic signatures and functional diversity of single-cell lineages. **2023**, 39, ○
- 16 Epimutations and Their Effect on Chromatin Organization: Exciting Avenues for Cancer Treatment. **2023**, 15, 215 ○
- 15 Epigenetic Perspective of Immunotherapy for Cancers. **2023**, 12, 365 ○
- 14 The Prospects of RNAs and Common Significant Pathways in Cancer Therapy and Regenerative Medicine. **2023**, 331-390 ○
- 13 Is 18F-FDG/18F-Choline Dual-Tracer PET Behavior a Surrogate of Tumor Differentiation in Hepatocellular Carcinoma. Publish Ahead of Print, ○
- 12 Generation of novel oncolytic vaccinia virus with improved intravenous efficacy through protection against complement-mediated lysis and evasion of neutralization by vaccinia virus-specific antibodies. **2023**, 11, e006024 ○
- 11 Modulation of epigenetic methylation enzymes by synthetic and natural agents. **2023**, 325-357 ○
- 10 Advances in epigenetic modifications and cervical cancer research. **2023**, 1878, 188894 ○

- 9 Near-Death Cells Cause Chemotherapy-Induced Metastasis via ATF4-Mediated NF- κ B Signaling Activation. **2023**, 10,
- 8 The Emerging Role of Epigenetics in Metabolism and Endocrinology. **2023**, 12, 256
- 7 Cell State Transitions and Phenotypic Heterogeneity in Luminal Breast Cancer Implicating MicroRNAs as Potential Regulators. **2023**, 24, 3497
- 6 Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies. **2023**, 8,
- 5 Inhibitors targeting epigenetic modifications in cancer. **2023**, 287-324
- 4 Chemopreventive Activity of Ellagitannins from *Acer pseudosieboldianum* (Pax) Komarov Leaves on Prostate Cancer Cells. **2023**, 12, 1047
- 3 Tumor Metabolism: Challenges and Future Perspectives. **2023**, 1-27
- 2 Early epigenetic markers for precision medicine. **2023**,
- 1 Epigenetic Conservation Infers That Colorectal Cancer Progenitors Retain The Phenotypic Plasticity Of Normal Colon.